RXRX

Business Context and Reporting Period

Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: Recursion is a clinical-stage TechBio company utilizing the Recursion Operating System (OS) to industrialize drug discovery through AI and wet-lab integration. The company operates as a single segment and has not yet commercialized any products. As of June 30, 2025, the company held an accumulated deficit of $1.8 billion.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 33% year-over-year for the quarter and 20% for the six-month period, driven by timing of projects from collaborations with Sanofi, Roche, and Merck KGaA.
• Expense Expansion: Operating costs and expenses surged 70% for the quarter and 78% for the six-month period.
  • R&D Expenses: Increased 74% (quarter) and 83% (six months), primarily due to the inclusion of Exscientia operations, Tempus data purchases ($22.7M in Q2, $49.9M in six months), and increased personnel costs.
  • G&A Expenses: Increased 47% (quarter) and 60% (six months), driven by Exscientia integration, higher salaries, and $8.4 million in severance costs from a June 2025 workforce reduction.
• Net Loss: Net loss widened significantly, increasing 76% for the quarter and 98% for the six-month period compared to 2024.
• Acquisition Impact: The November 2024 acquisition of Exscientia plc contributed $12.7 million in revenue and $72.1 million in operating loss for the six months ended June 30, 2025.

Guidance, Outlook, and Risks

• Liquidity: Management believes existing cash and cash equivalents ($525.1 million) are sufficient to fund operations for at least the next 12 months. The company expects to incur substantial operating losses in the future and will require additional capital.
• Restructuring: In June 2025, the company announced a workforce reduction of approximately 20%, estimating $9.3 million in charges. This is intended to streamline operations and improve post-integration efficiencies.
• Pipeline Updates:
  • REC-1245 (RBM39): Phase 1/2 DAHLIA study ongoing; early safety/PK data expected in 1H26.
  • REC-617 (CDK7): Combination dose escalation initiated in 1H25; additional monotherapy data expected in 2H25.
  • REC-102 (ENPP1): Full rights acquired from Rallybio; Phase 1 initiation on track for 2H26.
• Internal Controls: Disclosure controls and procedures were deemed ineffective as of June 30, 2025, due to a material weakness in internal control over financial reporting related to revenue recognition and the integration of Exscientia. Remediation efforts are ongoing but not yet complete.
• Legal Proceedings: Pending class action lawsuits regarding Exscientia's pre-acquisition disclosures and a dispute with a landlord regarding the Industry Lease in Salt Lake City. No liability has been recorded as an unfavorable outcome is not currently deemed probable.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $525.1 million cash balance against the accelerating operating cash burn of $208.4 million over six months.
• Exscientia Integration: Assess the progress of integrating Exscientia's operations and the timeline for finalizing the purchase price allocation.
• Internal Control Remediation: Monitor the status of remediation for the material weakness in internal controls over financial reporting, specifically regarding revenue recognition.
• Restructuring Execution: Track the realization of cost savings from the 20% workforce reduction announced in June 2025.
• Collaboration Milestones: Review the timing and probability of achieving the next set of milestone payments from Sanofi, Roche, and Merck KGaA to offset R&D costs.